| __timestamp | Ascendis Pharma A/S | Lantheus Holdings, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 6274000 | 72429000 |
| Thursday, January 1, 2015 | 9415000 | 78634000 |
| Friday, January 1, 2016 | 11504000 | 75374000 |
| Sunday, January 1, 2017 | 13482000 | 92157000 |
| Monday, January 1, 2018 | 25057000 | 93326000 |
| Tuesday, January 1, 2019 | 48473000 | 103132000 |
| Wednesday, January 1, 2020 | 76669000 | 110171000 |
| Friday, January 1, 2021 | 160180000 | 218817000 |
| Saturday, January 1, 2022 | 221227000 | 233827000 |
| Sunday, January 1, 2023 | 264410000 | 267194000 |
| Monday, January 1, 2024 | 284545000 |
Igniting the spark of knowledge
In the competitive landscape of the pharmaceutical and healthcare sectors, understanding spending patterns is crucial. Ascendis Pharma A/S and Lantheus Holdings, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses over the past decade. From 2014 to 2023, Ascendis Pharma's SG&A expenses skyrocketed by over 4,100%, reflecting its aggressive growth strategy. In contrast, Lantheus Holdings saw a more modest increase of approximately 270%, indicating a steady expansion approach. Notably, both companies reached their peak SG&A spending in 2023, with Ascendis Pharma at $264 million and Lantheus Holdings at $267 million. This data highlights the dynamic nature of financial strategies in the industry, where companies balance between rapid growth and sustainable expansion. As the healthcare landscape evolves, these spending patterns offer insights into the strategic priorities of leading firms.
Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Ascendis Pharma A/S
Cost Management Insights: SG&A Expenses for Incyte Corporation and Ascendis Pharma A/S
Who Optimizes SG&A Costs Better? Dr. Reddy's Laboratories Limited or Ascendis Pharma A/S
Operational Costs Compared: SG&A Analysis of Ascendis Pharma A/S and CRISPR Therapeutics AG
Ascendis Pharma A/S or Xenon Pharmaceuticals Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Ascendis Pharma A/S and PTC Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Ascendis Pharma A/S or Galapagos NV
Ascendis Pharma A/S or Evotec SE: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs ImmunityBio, Inc.
Operational Costs Compared: SG&A Analysis of Lantheus Holdings, Inc. and Ligand Pharmaceuticals Incorporated
Lantheus Holdings, Inc. and Novavax, Inc.: SG&A Spending Patterns Compared